ScreenerHero
BCRXBioCryst Pharmaceuticals, Inc.
NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · biocryst.com
9.800USD-2.68%Mkt Cap: 2.57B $P/E: —

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuramini…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$15.34BUSDP/E 117.3
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap2.57B $
Enterprise Value2.95B $
Revenue (TTM)940.61M $
Gross Profit855.76M $
Net Income (TTM)263.86M $
Revenue/Share4.099 USD
Last Price9.800 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees435
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS09058V1035
Valuation
P/E (Trailing)—
P/E (Forward)10.28
PEG9.39
EV/EBITDA6.81
EV/Revenue3.14
P/S2.62
P/B-5.43
EPS (TTM)-1.34
EPS (Forward)0.94
52W Range
6.00073% of range11.22
52W High11.22 USD
52W Low6.000 USD
Profitability
Gross Margin97.82%
Oper. Margin45.12%
EBITDA Margin46.10%
Profit Margin30.16%
ROE-221.45%
ROA51.32%
Growth
Revenue Growth33.60%
Earnings Growth1400.00%
Cash Flow & Leverage
Operating CF347.37M $
CapEx (TTM)2.47M $
FCF Margin34.47%
FCF Yield12.60%
Net Debt484.07M $
Net Debt/EBITDA1.12
Balance Sheet
Debt/Equity-3.68
Current Ratio2.32
Quick Ratio2.22
Book Value/Sh-1.7800 USD
Cash/Share1.380 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)20.82 USD
Upside (mean)+112.4%
Target Range12.00 USD – 32.00 USD
$12.00+112.4% to mean$32.00
# Analysts11
Ownership
Shares Out.255.54M
Float222.36M
Insiders1.20%
Institutions105.35%
Short Interest
Short Ratio8.1d
Short % Float12.93%
Short % Out.12.84%
Shares Short32.80M
Short (prev mo.)48.69M
Technical
SMA 509.573 (+2.4%)
SMA 2008.418 (+16.4%)
Beta0.55
S&P 52W Chg18.16%
Avg Vol (30d)3.59M
Avg Vol (10d)3.52M
Technical Indicators
RSI (14)56.6
MACD0.1528
MACD Signal0.0851
MACD Hist.+0.0677
BB Upper10.48 USD
BB Middle9.560 USD
BB Lower8.643 USD
BB Width19.19%
ATR (14)0.4820 USD
Vol Ratio (20d)0.86x